Stock EXAS EXACT SCIENCES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Exact Sciences Corporation

Equities

EXAS

US30063P1057

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
63.24 USD -0.46% Intraday chart for Exact Sciences Corporation +0.03% -14.52%
Apr. 17 Exact Sciences Corporation announced that it has received $266.75 million in funding CI
Apr. 15 Sector Update: Health Care Stocks Advance Premarket Monday MT

Summary

  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The company has insufficient levels of profitability.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • The company's enterprise value to sales, at 4.58 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-14.52% 11.48B
A-
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+44.03% 3.27B
D+
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-33.09% 2.2B
C
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-18.60% 2.05B -
B-
VERACYTE, INC. Stock Veracyte, Inc.
-27.59% 1.49B
C+
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+17.10% 1.01B
B-
SEEGENE, INC. Stock Seegene, Inc.
-3.06% 743M
C+
CAREDX, INC Stock CareDx, Inc
-33.50% 413M
C-
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-46.94% 377M
C-
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+27.44% 374M - -
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. Ratings Exact Sciences Corporation